BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27485167)

  • 21. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.
    Chiu K; Lee L; Cheung S; Churg AM
    Mod Pathol; 2018 Sep; 31(9):1400-1403. PubMed ID: 29785020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
    Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
    [No Abstract]   [Full Text] [Related]  

  • 26. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
    Klebe S; Swalling A; Jonavicius L; Henderson DW
    J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in malignant pleural mesothelioma.
    Davidson B
    Hum Pathol; 2015 Jun; 46(6):789-804. PubMed ID: 25824607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
    Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
    Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Takeshima Y
    Mod Pathol; 2017 May; 30(5):672-681. PubMed ID: 28128276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
    Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
    Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
    Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
    Hu Y; Yang Q; McMahon LA; Wang HL; Xu H
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):411-3. PubMed ID: 20436345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
    Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
    World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers and prognostic factors for malignant pleural mesothelioma.
    Vigneri P; Martorana F; Manzella L; Stella S
    Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What's new in mesothelioma.
    Ascoli V; Murer B; Nottegar A; Luchini C; Carella R; Calabrese F; Lunardi F; Cozzi I; Righi L
    Pathologica; 2018 Mar; 110(1):12-28. PubMed ID: 30259910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.